Page 180 - Multidisipliner Covid 19

BÖLÜM 10

Song C (2020) In vitro antiviral activity and projection of optimized
dosing design of hydroxychloroquine for the treatment of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical Infectious
Diseases
31. https://www.recoverytrial.net/news/statement-from-the-chief-inves-
tigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-
trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-
of-hydroxychloroquine-in-hospitalised-patients-with-covid-19 RtiNcb-
fuohihpwC- ((Accessed on June 08, 2020).).
32. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, Wu Y, Xiao W, Liu
S, Chen E (2020) Hydroxychloroquine in patients with mainly mild
to moderate coronavirus disease 2019: open label, randomised con-
trolled trial. bmj 369
33. Chen C-Y, Wang F-L, Lin C-C (2006) Chronic hydroxychloroquine use
associated with QT prolongation and refractory ventricular arrhythmia.
Clinical Toxicology 44 (2):173-175
34. Juurlink DN (2020) Safety considerations with chloroquine, hydroxy-
chloroquine and azithromycin in the management of SARS-CoV-2
infection. CMAJ 192 (17):E450-E453
35. Choy K-T, Wong AY-L, Kaewpreedee P, Sia S-F, Chen D, Hui KPY, Chu
DKW, Chan MCW, Cheung PP-H, Huang X (2020) Remdesivir, lopi-
navir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication
in vitro. Antiviral research:104786
36. Mentré F, Taburet A-M, Guedj J, Anglaret X, Keïta S, de Lamballerie
X, Malvy D (2015) Dose regimen of favipiravir for Ebola virus disease.
The Lancet Infectious Diseases 15 (2):150-151
37. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, Liao X, Gu Y, Cai Q, Yang
Y (2020) Experimental treatment with favipiravir for COVID-19: an
open-label control study. Engineering
38. Chen C, Huang J, Cheng Z, Wu J, Chen S, Zhang Y, Chen B, Lu M,
Luo Y, Zhang J (2020) Favipiravir versus arbidol for COVID-19: a ran-
domized clinical trial. MedRxiv
39. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M,
Xing L (2020) Treatment of 5 critically ill patients with COVID-19 with
convalescent plasma. Jama 323 (16):1582-1589
40. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S,
Hu Y (2020) Effectiveness of convalescent plasma therapy in severe

179